BMS reports mixed results for Opdivo in lung cancer trial - Drug Development Technology

BMS reports mixed results for Opdivo in lung cancer trial  Drug Development Technology

BMS has reported mixed results from the Phase III CheckMate -227 trial of Opdivo in combination with chemotherapy or its other drug Yervoy.



Comments

Popular posts from this blog

Stage 4 Lung Cancer Life Expectancy

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Free biotech stocks directory, pharma stocks, telemedicine stocks ...